Detalhe da pesquisa
1.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Blood
; 141(20): 2470-2482, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821767
2.
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
Cancer
; 127(22): 4190-4197, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34343354
3.
Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
Eur J Haematol
; 107(5): 529-542, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34270825
4.
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trials.
Eur J Haematol
; 103(3): 255-267, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31231828
5.
Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER).
Haematologica
; 108(8): 2244-2248, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601981
6.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Br J Haematol
; 176(5): 770-782, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27983764
7.
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Blood
; 126(12): 1407-14, 2015 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26239087
8.
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.
Ann Hematol
; 96(6): 895-904, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28331964
9.
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Lancet Oncol
; 17(1): 57-66, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26655425
10.
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Blood
; 123(26): 4027-36, 2014 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24797300
11.
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Br J Cancer
; 113(6): 872-7, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26335608
12.
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Blood
; 121(23): 4769-77, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23632886
13.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Lancet
; 381(9873): 1203-10, 2013 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23433739
14.
Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Oncologist
; 18(8): 954-64, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23900001
15.
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
Haematologica
; 97(3): 393-401, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22058219
16.
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.
Mol Ther
; 19(5): 990-9, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21189474
17.
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Lancet Oncol
; 11(6): 521-9, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20493771
18.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leuk Lymphoma
; 62(14): 3440-3451, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34414843
19.
Late-onset hemophagocytic lymphohistiocytosis (HLH) in an adult female with Griscelli syndrome type 2 (GS2).
Ann Hematol
; 94(6): 1057-60, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25544030
20.
Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab.
Eur J Haematol
; 84(6): 547-9, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20113334